[HTML][HTML] MicroRNA-34a, prostate cancer stem cells, and therapeutic development

W Li, X Liu, EM Dougherty, DG Tang - Cancers, 2022 - mdpi.com
Simple Summary Prostate cancer is still the most common cancer among men in the US.
Current standard-of-care therapies for metastatic castration-resistant prostate cancer can …

[HTML][HTML] MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

WJ Li, X Liu, EM Dougherty, DG Tang - Cancers, 2022 - ncbi.nlm.nih.gov
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with
multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in …

[PDF][PDF] MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

W Li, X Liu, EM Dougherty, DG Tang - Cancer, 2006 - academia.edu
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with
multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in …

MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

WJ Li, X Liu, EM Dougherty, DG Tang - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with
multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in …

MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development.

WJ Li, X Liu, EM Dougherty, DG Tang - Cancers, 2022 - europepmc.org
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with
multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in …

MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

WJ Li, X Liu, EM Dougherty, DG Tang - Cancers, 2022 - search.proquest.com
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with
multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in …